Japan Tissue Engineering Co (TSE:7774) NonCurrent Deferred Liabilities: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
61 GF Score
Price 円605.00
GF Value 円517.85
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co NonCurrent Deferred Liabilities?

Japan Tissue Engineering Co TSE:7774 -1.94% 61 NonCurrent Deferred Liabilities is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 61/100 and a GF Value™ of 円517.85 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Japan Tissue Engineering Co's non-current deferred liabilities for the quarter that ended in Mar. 2026 was 円0 Mil.

Japan Tissue Engineering Co NonCurrent Deferred Liabilities Related Terms

Japan Tissue Engineering Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co NonCurrent Deferred Liabilities Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Japan Tissue Engineering Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:7774
61GF Score
Japan Tissue Engineering Co Ltd TSE:7774
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of 円0 Mil mean?
Japan Tissue Engineering Co (TSE:7774) has a NonCurrent Deferred Liabilities of 円0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's NonCurrent Deferred Liabilities too high?
Japan Tissue Engineering Co's current NonCurrent Deferred Liabilities is 円0 Mil. Overall, Japan Tissue Engineering Co has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Japan Tissue Engineering Co's NonCurrent Deferred Liabilities of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current NonCurrent Deferred Liabilities is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.85, compared to a current price of 円605.00 — trading 16.8% above its estimated fair value. The current NonCurrent Deferred Liabilities is 円0 Mil. Japan Tissue Engineering Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current NonCurrent Deferred Liabilities is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円605.00 is trading 16.8% above its estimated GF Value™ of 円517.85. GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.

Key valuation signals for TSE:7774:

  • NonCurrent Deferred Liabilities: 円0 Mil
  • GF Value™: 円517.85 vs. price of 円605.00 (16.8% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
61GF Score

Get the complete analysis for TSE:7774

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円605.00
Price
円517.85
GF Value